FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
15 letters match. Newest first.
-
DrugsNatural Essentials, Inc.
FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.
High risk -
DrugsPritam International Private Limited
Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.
High risk -
DrugsEurofins SF Analytical Laboratories, Inc.
FDA warned Eurofins SF Analytical Laboratories, a contract drug-testing lab, that it kept incomplete microbial test records and skipped required investigations.
High risk -
DrugsCuria New York, Inc.
FDA warned Curia New York's Rensselaer, New York API plant that undocumented lab injections, shredded records and shared passwords violate CGMP.
High risk -
DrugsAuriga Research Pvt. Ltd.
Auriga Research, an Indian contract drug testing lab, failed to keep complete lab records and properly investigate failing test results.
High risk -
DrugsDabur India Limited
FDA cites Dabur India for falsified records, incomplete lab data, and inadequate cleaning and process validation for over-the-counter drugs.
High risk -
DrugsWizcure Pharmaa Private Limited
FDA warned Wizcure Pharmaa about serious manufacturing and data-integrity failures in sterile OTC drugs.
High risk -
BiologicsGenzyme Ireland Limited
Genzyme Ireland's Waterford biologics plant cited for quality unit and data integrity failures across two licensed products.
High risk -
DrugsHuons Co., Ltd.
FDA cites Huons in South Korea for data integrity and sterility failures in drug manufacturing.
High risk -
DrugsPharmathen International S.A.
FDA warns Pharmathen over inadequate aseptic controls at its Greek plant making sterile drugs for the U.S.
High risk -
DrugsLaboratorios Jaloma S.A. de C.V.
FDA found Laboratorios Jaloma’s OTC drug lab records were inaccurate, microbial tests unvalidated, and electronic data missing or uncontrolled.
High risk -
DrugsAva Inc.
FDA warned Ava Inc. about adulterated drugs after an inspection found data-integrity failures and hidden trial injections in its Willowbrook, Illinois lab.
High risk -
DrugsFulijaya Manufacturing SDN. BHD.
Fulijaya Manufacturing in Malaysia failed CGMP (drug manufacturing rules) for OTC drugs, with missing lab data, flawed microbial tests, and weak stability data.
High risk -
DrugsUnipack LLC
FDA says Unipack LLC released suppositories without adequate out-of-specification investigations, complete lab records, and required USP testing.
High risk -
DrugsSV Labs Corporation
SV Labs released microbe-contaminated OTC drug products and lacked water, process and quality controls, FDA says.
High risk